GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function
Cell Reports · 2023-11 · 42 (11) · 113326
DOI: 10.1016/j.celrep.2023.113326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-11. Verfasst von Nour Zaïmia und 8 weiteren Autor:innen. Beteiligte Einrichtung: IGF, Université Montpellier, CNRS, INSERM, Montpellier, France. Hauptthemen laut MEDLINE: Insulin-Secreting Cells. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre Hospitalier Régional Universitaire de Montpellier, Institut National de la Santé et de la Recherche Médicale, Université de Montpellier.
Abstract (Originalsprache)
Glucagon-like peptide 1 (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIPR) receptors are G-protein-coupled receptors involved in glucose homeostasis. Diabetogenic conditions decrease β-arrestin 2 (ARRB2) levels in human islets. In mouse β cells, ARRB2 dampens insulin secretion by partially uncoupling cyclic AMP (cAMP)/protein kinase A (PKA) signaling at physiological doses of GLP-1, whereas at pharmacological doses, the activation of extracellular signal-related kinase (ERK)/cAMP-responsive element-binding protein (CREB) requires ARRB2. In contrast, GIP-potentiated insulin secretion needs ARRB2 in mouse and human islets. The GIPR-ARRB2 axis is not involved in cAMP/PKA or ERK signaling but does mediate GIP-induced F-actin depolymerization. Finally, the dual GLP-1/GIP agonist tirzepatide does not require ARRB2 for the potentiation of insulin secretion. Thus, ARRB2 plays distinct roles in regulating GLP-1R and GIPR signaling, and we highlight (1) its role in the physiological context and the possible functional consequences of its decreased expression in pathological situations such as diabetes and (2) the importance of assessing the signaling pathways engaged by the agonists (biased/dual) for therapeutic purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IGF, Université Montpellier, CNRS, INSERM, Montpellier, France.
- LTCD, IRMB, CHU Montpellier, Montpellier, France.
- Université Catholique de Louvain, Institut de Recherche Expérimental et Clinique, Pôle d'Endocrinologie, Diabète, et Nutrition, Brussels, Belgium.
- IGF, Université Montpellier, CNRS, INSERM, Montpellier, France. Electronic address: magalie.ravier@igf.cnrs.fr.
Förderung
- Centre Hospitalier Régional Universitaire de Montpellier
- Institut National de la Santé et de la Recherche Médicale
- Université de Montpellier
- Fonds De La Recherche Scientifique - FNRS
- Société Francophone du Diabète
- Fondation pour la Recherche Médicale
- Medical Research Institute Sri Lanka
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Zaïmia, N., Obeid, J., Varrault, A., Sabatier, J., Broca, C., Gilon, P., Costes, S., Bertrand, G., & Ravier, M. A. (2023). GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell Reports, 42(11), 113326. https://doi.org/10.1016/j.celrep.2023.113326
Vancouver
Zaïmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell Reports. 2023;42(11):113326. doi:10.1016/j.celrep.2023.113326
BibTeX
@article{Zamia2023,
author = {Zaïmia, Nour and Obeid, Joelle and Varrault, Annie and Sabatier, Julia and Broca, Christophe and Gilon, Patrick and Costes, Safia and Bertrand, Gyslaine and Ravier, Magalie A},
title = {GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {11},
pages = {113326},
doi = {10.1016/j.celrep.2023.113326}
}
EUVIMED